EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:EKSO • US2826444000

10.38 USD
+1.02 (+10.9%)
Last: Feb 6, 2026, 03:32 PM
Fundamental Rating

2

Overall EKSO gets a fundamental rating of 2 out of 10. We evaluated EKSO against 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of EKSO have multiple concerns. EKSO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year EKSO has reported negative net income.
  • EKSO had a negative operating cash flow in the past year.
  • EKSO had negative earnings in each of the past 5 years.
  • EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -49.21%, EKSO is doing worse than 66.13% of the companies in the same industry.
  • EKSO has a worse Return On Equity (-110.14%) than 62.37% of its industry peers.
Industry RankSector Rank
ROA -49.21%
ROE -110.14%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • With a Gross Margin value of 53.48%, EKSO perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EKSO has grown nicely.
  • The Profit Margin and Operating Margin are not available for EKSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EKSO has more shares outstanding
  • The number of shares outstanding for EKSO has been increased compared to 5 years ago.
  • EKSO has a better debt/assets ratio than last year.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • EKSO has an Altman-Z score of -15.72. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
  • EKSO has a worse Altman-Z score (-15.72) than 83.33% of its industry peers.
  • EKSO has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of EKSO (0.31) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -15.72
ROIC/WACCN/A
WACC9.73%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.66 indicates that EKSO should not have too much problems paying its short term obligations.
  • EKSO's Current ratio of 1.66 is on the low side compared to the rest of the industry. EKSO is outperformed by 69.89% of its industry peers.
  • EKSO has a Quick Ratio of 1.09. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.09, EKSO is doing worse than 72.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.09
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.74%, which is quite impressive.
  • EKSO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.59%.
  • The Revenue has been growing slightly by 5.19% on average over the past years.
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%

3.2 Future

  • Based on estimates for the next years, EKSO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.47% on average per year.
  • Based on estimates for the next years, EKSO will show a quite strong growth in Revenue. The Revenue will grow by 10.94% on average per year.
EPS Next Y74.41%
EPS Next 2Y39.68%
EPS Next 3Y25.84%
EPS Next 5Y16.47%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y10.94%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EKSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • EKSO's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.68%
EPS Next 3Y25.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (2/6/2026, 3:32:20 PM)

10.38

+1.02 (+10.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28
Earnings (Next)N/A
Inst Owners7.68%
Inst Owner Change-38.23%
Ins Owners6.59%
Ins Owner Change0.42%
Market Cap35.19M
Revenue(TTM)14.75M
Net Income(TTM)-10.66M
Analysts80
Price Target9.69 (-6.65%)
Short Float %9.65%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.86%
Min EPS beat(2)9.95%
Max EPS beat(2)53.76%
EPS beat(4)2
Avg EPS beat(4)-3.7%
Min EPS beat(4)-71.57%
Max EPS beat(4)53.76%
EPS beat(8)4
Avg EPS beat(8)-15.61%
EPS beat(12)5
Avg EPS beat(12)-10.05%
EPS beat(16)8
Avg EPS beat(16)-7.85%
Revenue beat(2)0
Avg Revenue beat(2)-28.94%
Min Revenue beat(2)-53.24%
Max Revenue beat(2)-4.65%
Revenue beat(4)0
Avg Revenue beat(4)-21.89%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-1.24%
Revenue beat(8)0
Avg Revenue beat(8)-18.43%
Revenue beat(12)3
Avg Revenue beat(12)-9.03%
Revenue beat(16)4
Avg Revenue beat(16)-6.14%
PT rev (1m)22.58%
PT rev (3m)-72.66%
EPS NQ rev (1m)41.84%
EPS NQ rev (3m)54.03%
EPS NY rev (1m)37.28%
EPS NY rev (3m)51.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.39
P/FCF N/A
P/OCF N/A
P/B 3.64
P/tB 6.91
EV/EBITDA N/A
EPS(TTM)-5.68
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS4.35
BVpS2.86
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.21%
ROE -110.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.48%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score4
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.46%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.09
Altman-Z -15.72
F-Score4
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y74.41%
EPS Next 2Y39.68%
EPS Next 3Y25.84%
EPS Next 5Y16.47%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%2.37%
Revenue Next Year-17.71%
Revenue Next 2Y12.81%
Revenue Next 3Y10.94%
Revenue Next 5YN/A
EBIT growth 1Y6.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.95%
OCF growth 3YN/A
OCF growth 5YN/A

EKSO BIONICS HOLDINGS INC / EKSO FAQ

Can you provide the ChartMill fundamental rating for EKSO BIONICS HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to EKSO.


What is the valuation status for EKSO stock?

ChartMill assigns a valuation rating of 1 / 10 to EKSO BIONICS HOLDINGS INC (EKSO). This can be considered as Overvalued.


What is the profitability of EKSO stock?

EKSO BIONICS HOLDINGS INC (EKSO) has a profitability rating of 1 / 10.


Can you provide the financial health for EKSO stock?

The financial health rating of EKSO BIONICS HOLDINGS INC (EKSO) is 2 / 10.


Can you provide the expected EPS growth for EKSO stock?

The Earnings per Share (EPS) of EKSO BIONICS HOLDINGS INC (EKSO) is expected to grow by 74.41% in the next year.